This Viewpoint describes reforms to the ways the National Health Service (NHS) appraises cost-effectiveness and coverage of cancer drugs in England and Wales, the role of the National Institute for Health and Care Excellence (NICE) in the process, and changes in drug approval rates and access to new drugs as a result.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2BIhWGd
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Objectives Greece is one of the leading tobacco-producing countries in European Union, and every year over 19 000 Greeks die from tobacco-at...
-
Objectives Drug interactions, poor adherence to medication and high-risk sexual behaviour may occur in individuals with HIV using recreation...
-
Introduction Multimorbidity (MM) refers to the coexistence of two or more chronic conditions within one person, where no one condition is co...
-
Objective To describe the prevalence and severity of diabetic retinopathy (DR) and sight-threatening DR (STDR) among Chinese adults with dia...
-
Related Articles Three job stress models and their relationship with musculoskeletal pain in blue- and white-collar workers. J Psycho...
-
Abstract Background Mature T-cell and natural killer (NK)-cell lymphomas compose a heterogeneous group of non-Hodgkin lymphomas, and ext...
-
<span class="paragraphSection"><div class="boxTitle">Abstract</div>Masked hypertension (MHT), defined ...
-
Background Hepatitis B virus (HBV) transmission is known to occur through direct contact with infected blood. There has been some suspicion ...
-
In Rwanda, the prevalence of viral hepatitis (HCV) is poorly understood. The current study investigated the prevalence and risk factors of H...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου